Table 3.
MEG treatment moderators on patient-reported cognitive complaints
| CRT vs. ETAU | MBCT vs. ETAU | |||||||
|---|---|---|---|---|---|---|---|---|
| Post-treatment | 6-month follow-up | Post-treatment | 6-month follow-up | |||||
| β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | |
| Spectral | ||||||||
| Power delta | 67.8 (− 28.1, 163.7) | 0.166 | 40.8 (− 55.1, 136.7) | 0.405 | 85.1 (− 50.8, 221.0) | 0.220 | 13.1 (− 123.6, 149.8) | 0.851 |
| Power theta | 64.6 (− 45.3, 174.5) | 0.249 | 42.7 (− 66.9, 152.4) | 0.445 | − 8.8 (− 146.7, 129.2) | 0.901 | 1.3 (− 136.6, 139.1) | 0.986 |
| Power alpha1 | − 64.6 (− 231.4, 102.2) | 0.448 | 6.3 (− 159.9, 172.6) | 0.940 | − 63.9 (− 267.8, 139.9) | 0.539 | − 27.0 (− 230.9, 177.0) | 0.796 |
| Power alpha2 | − 43.0 (− 229.5, 143.6) | 0.652 | 9.3 (− 177.3, 195.8) | 0.923 | − 41.8 (− 248.9, 165.3) | 0.692 | 60.6 (− 153.1, 274.3) | 0.579 |
| Power beta | − 83.6 (− 172.8, 5.6) | 0.066 | − 76.7 (− 165.8, 12.5) | 0.092 | − 49.6 (− 148.8, 49.7) | 0.328 | − 49.6 (− 149.1, 49.9) | 0.329 |
| Power gamma | 147.0 (− 137.0, 431.0) | 0.310 | 8.1 (− 275.7, 291.9) | 0.955 | − 22.1 (− 328.9, 284.8) | 0.888 | − 9.5 (− 316.0, 297.1) | 0.952 |
| Connectivity | ||||||||
| PLI theta | 561.1 (− 830.3, 1952.5) | 0.429 | − 217.4 (− 1599.1, 1164.4) | 0.758 | 64.0 (− 2254.4, 2382.3) | 0.957 | − 12.4 (− 2323.2, 2298.4) | 0.992 |
| PLI beta | − 1253.8 (3182.1, 674.4) | 0.202 | − 770.8 (− 2699.0, 1157.4) | 0.433 | − 1067.1 (− 3467.6, 1333.5) | 0.384 | − 1129.4 (− 3529.7, 1270.8) | 0.356 |
| PLI DMN theta | 602.6 (− 831.1, 2036.2) | 0.410 | − 15.1 (− 1441.7, 1411.4) | 0.983 | − 294.8 (− 2604.5, 2015.0) | 0.802 | − 402.5 (− 2706.3, 1901.3) | 0.732 |
| PLI DMN beta | − 1453.4 (− 3411.1, 504.3) | 0.146 | − 1071.5 (− 3028.9, 885.8) | 0.283 | − 910.8 (− 3497.1, 1675.4) | 0.490 | − 815.0 (− 3400.4, 1770.3) | 0.537 |
| Integration | ||||||||
| TH delta | 219.3 (− 277.8, 716.5) | 0.387 | 389.4 (− 102.7, 881.5) | 0.121 | 228.4 (− 297.7, 754.5) | 0.395 | − 100.8 (− 622.6, 421.1) | 0.705 |
| TH alpha1 | − 253.0 (− 764.5, 258.5) | 0.332 | − 43.6 (− 553.3, 466.0) | 0.867 | 28.5 (− 460.2, 517.3) | 0.909 | − 271.2 (− 760.5, 218.1) | 0.277 |
| TH alpha2 | 15.9 (− 504.7, 536.6) | 0.952 | 140.0 (− 369.3, 649.3) | 0.590 | 109.4 (− 418.5, 637.3) | 0.685 | − 87.6 (− 604.2, 429.0) | 0.740 |
| TH beta | − 359.2 (− 895.2, 176.7) | 0.189 | − 37.9 (− 570.1, 494.4) | 0.889 | 436.3 (− 213.1, 1085.7) | 0.188 | 420.8 (− 226.7, 1068.2) | 0.203 |
| TH gamma | -56.9 (− 530.3, 416.4) | 0.814 | 107.9 (− 360.5, 576.3) | 0.652 | − 386.0 (− 968.3, 196.3) | 0.194 | − 334.7 (− 916.4, 247.1) | 0.260 |
CRT cognitive rehabilitation therapy, MBCT mindfulness-based cognitive therapy, ETAU enhanced treatment as usual, PLI phase lag index, DMN default mode network, TH tree hierarchy
Treatment moderators of the effects on patient-reported cognitive complaints (i.e., Cognitive Failures Questionnaire (CFQ)), corrected for age, education, sex, and baseline CFQ scores. *Significant moderator p < 0.05. **Significant moderator after multiple comparison correction: power p < 0.008 (corrected for six frequency bands), PLI p < 0.025 (corrected for two frequency bands), TH p < 0.01 (corrected for five frequency bands)